| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colitis, Ulcerative | 68 | 2023 | 711 | 9.990 |
Why?
|
| Crohn Disease | 61 | 2023 | 730 | 7.760 |
Why?
|
| Inflammatory Bowel Diseases | 36 | 2023 | 549 | 4.900 |
Why?
|
| Gastrointestinal Agents | 21 | 2020 | 161 | 3.090 |
Why?
|
| Antibodies, Monoclonal | 26 | 2020 | 1376 | 2.370 |
Why?
|
| Mesalamine | 15 | 2017 | 88 | 2.320 |
Why?
|
| Immunosuppressive Agents | 21 | 2020 | 977 | 2.270 |
Why?
|
| Antibodies, Monoclonal, Humanized | 15 | 2020 | 930 | 2.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 15 | 2017 | 243 | 2.010 |
Why?
|
| Infliximab | 30 | 2022 | 151 | 1.780 |
Why?
|
| Remission Induction | 24 | 2023 | 722 | 1.440 |
Why?
|
| Tumor Necrosis Factor-alpha | 16 | 2022 | 683 | 1.290 |
Why?
|
| Cost of Illness | 5 | 2015 | 150 | 1.270 |
Why?
|
| Biological Products | 6 | 2021 | 143 | 1.270 |
Why?
|
| Anti-Inflammatory Agents | 11 | 2020 | 339 | 1.220 |
Why?
|
| Mercaptopurine | 11 | 2020 | 53 | 1.170 |
Why?
|
| Colitis | 5 | 2022 | 239 | 1.160 |
Why?
|
| Azathioprine | 12 | 2020 | 125 | 1.140 |
Why?
|
| Humans | 152 | 2023 | 86601 | 1.110 |
Why?
|
| Cyclosporine | 11 | 2019 | 234 | 1.070 |
Why?
|
| Janus Kinase Inhibitors | 2 | 2023 | 19 | 1.060 |
Why?
|
| Colonic Diseases | 2 | 2022 | 65 | 1.010 |
Why?
|
| Proctocolectomy, Restorative | 6 | 2022 | 87 | 0.850 |
Why?
|
| Aminosalicylic Acids | 3 | 2008 | 42 | 0.850 |
Why?
|
| Biological Therapy | 4 | 2018 | 45 | 0.840 |
Why?
|
| Adult | 77 | 2023 | 25640 | 0.840 |
Why?
|
| Retrospective Studies | 43 | 2022 | 8475 | 0.830 |
Why?
|
| Employment | 3 | 2015 | 52 | 0.800 |
Why?
|
| Colonoscopy | 13 | 2021 | 264 | 0.790 |
Why?
|
| Colonic Pouches | 4 | 2022 | 67 | 0.750 |
Why?
|
| Economics, Pharmaceutical | 3 | 2010 | 9 | 0.750 |
Why?
|
| Male | 78 | 2023 | 40956 | 0.730 |
Why?
|
| Female | 81 | 2023 | 44507 | 0.720 |
Why?
|
| Critical Pathways | 1 | 2019 | 35 | 0.680 |
Why?
|
| Middle Aged | 59 | 2020 | 25017 | 0.650 |
Why?
|
| Leukocyte L1 Antigen Complex | 5 | 2023 | 39 | 0.640 |
Why?
|
| Gastroenterology | 1 | 2020 | 134 | 0.630 |
Why?
|
| Treatment Outcome | 32 | 2023 | 7988 | 0.620 |
Why?
|
| Intestinal Obstruction | 2 | 2016 | 88 | 0.600 |
Why?
|
| Health Resources | 3 | 2008 | 76 | 0.590 |
Why?
|
| Severity of Illness Index | 18 | 2021 | 1801 | 0.590 |
Why?
|
| Hospitalization | 9 | 2019 | 848 | 0.590 |
Why?
|
| Secondary Prevention | 7 | 2019 | 162 | 0.590 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.590 |
Why?
|
| Medication Adherence | 3 | 2012 | 129 | 0.580 |
Why?
|
| Proctitis | 3 | 2006 | 12 | 0.550 |
Why?
|
| Drug Resistance | 4 | 2019 | 256 | 0.540 |
Why?
|
| Communicable Diseases | 1 | 2016 | 63 | 0.530 |
Why?
|
| Pouchitis | 3 | 2021 | 44 | 0.530 |
Why?
|
| Insurance, Health | 2 | 2015 | 160 | 0.520 |
Why?
|
| Colectomy | 7 | 2020 | 167 | 0.520 |
Why?
|
| Opportunistic Infections | 2 | 2022 | 59 | 0.520 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.510 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.510 |
Why?
|
| Endoscopy, Gastrointestinal | 5 | 2019 | 153 | 0.500 |
Why?
|
| Young Adult | 19 | 2019 | 5974 | 0.500 |
Why?
|
| Ileum | 5 | 2021 | 159 | 0.490 |
Why?
|
| United States | 19 | 2022 | 6665 | 0.480 |
Why?
|
| Pregnancy Complications | 5 | 2020 | 336 | 0.480 |
Why?
|
| Dietary Fiber | 1 | 2014 | 43 | 0.480 |
Why?
|
| Health Expenditures | 1 | 2015 | 86 | 0.480 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 81 | 0.480 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.480 |
Why?
|
| Infusions, Intravenous | 5 | 2020 | 429 | 0.470 |
Why?
|
| Health Services | 2 | 2012 | 55 | 0.470 |
Why?
|
| Health Care Costs | 4 | 2012 | 237 | 0.470 |
Why?
|
| Follow-Up Studies | 16 | 2023 | 3636 | 0.470 |
Why?
|
| Adrenal Cortex Hormones | 10 | 2008 | 263 | 0.470 |
Why?
|
| Glucocorticoids | 4 | 2009 | 352 | 0.450 |
Why?
|
| Immunologic Factors | 6 | 2023 | 170 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1034 | 0.440 |
Why?
|
| Colonic Neoplasms | 5 | 2018 | 556 | 0.440 |
Why?
|
| Methotrexate | 4 | 2006 | 249 | 0.430 |
Why?
|
| Quality of Life | 7 | 2019 | 1583 | 0.430 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 363 | 0.420 |
Why?
|
| Clinical Trials as Topic | 6 | 2009 | 1169 | 0.400 |
Why?
|
| Piperidines | 3 | 2023 | 181 | 0.400 |
Why?
|
| Calcineurin Inhibitors | 4 | 2021 | 54 | 0.400 |
Why?
|
| Drug Therapy, Combination | 6 | 2020 | 894 | 0.390 |
Why?
|
| Postoperative Complications | 7 | 2022 | 2207 | 0.380 |
Why?
|
| Pregnancy Outcome | 3 | 2020 | 247 | 0.370 |
Why?
|
| Aged | 25 | 2021 | 18402 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 1961 | 0.360 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2023 | 52 | 0.360 |
Why?
|
| Drug Administration Schedule | 8 | 2019 | 916 | 0.360 |
Why?
|
| Prospective Studies | 17 | 2023 | 4210 | 0.350 |
Why?
|
| Intestinal Mucosa | 6 | 2020 | 797 | 0.350 |
Why?
|
| Risk Factors | 14 | 2020 | 5416 | 0.350 |
Why?
|
| Autoimmune Diseases | 3 | 2008 | 241 | 0.350 |
Why?
|
| Ustekinumab | 2 | 2020 | 47 | 0.350 |
Why?
|
| Colorectal Neoplasms | 4 | 2023 | 938 | 0.340 |
Why?
|
| Cutaneous Fistula | 1 | 2008 | 11 | 0.340 |
Why?
|
| Feces | 3 | 2021 | 319 | 0.340 |
Why?
|
| Intestinal Fistula | 1 | 2008 | 30 | 0.340 |
Why?
|
| Managed Care Programs | 1 | 2008 | 42 | 0.330 |
Why?
|
| Inflammation | 6 | 2023 | 920 | 0.330 |
Why?
|
| Adolescent | 12 | 2019 | 8979 | 0.320 |
Why?
|
| Gastrointestinal Diseases | 2 | 2020 | 146 | 0.320 |
Why?
|
| Colon | 4 | 2021 | 496 | 0.320 |
Why?
|
| Actinomycosis | 1 | 2007 | 12 | 0.310 |
Why?
|
| Adalimumab | 5 | 2021 | 80 | 0.310 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2020 | 206 | 0.310 |
Why?
|
| Steroids | 4 | 2020 | 177 | 0.310 |
Why?
|
| Vitamin D Deficiency | 2 | 2021 | 103 | 0.310 |
Why?
|
| Prognosis | 12 | 2020 | 3674 | 0.310 |
Why?
|
| Paternal Exposure | 2 | 2018 | 3 | 0.300 |
Why?
|
| Recurrence | 9 | 2021 | 1139 | 0.290 |
Why?
|
| Adenocarcinoma | 4 | 2019 | 1169 | 0.290 |
Why?
|
| Indans | 2 | 2023 | 31 | 0.290 |
Why?
|
| Macrophage-1 Antigen | 1 | 2006 | 17 | 0.290 |
Why?
|
| Oxadiazoles | 2 | 2023 | 46 | 0.280 |
Why?
|
| Antimetabolites | 1 | 2006 | 24 | 0.280 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2005 | 20 | 0.270 |
Why?
|
| Endoscopy | 4 | 2022 | 332 | 0.270 |
Why?
|
| Population Surveillance | 3 | 2016 | 219 | 0.270 |
Why?
|
| Lung Diseases | 1 | 2007 | 263 | 0.270 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2005 | 45 | 0.260 |
Why?
|
| Spermatozoa | 1 | 2004 | 62 | 0.250 |
Why?
|
| Postoperative Care | 1 | 2005 | 221 | 0.250 |
Why?
|
| Registries | 6 | 2018 | 702 | 0.240 |
Why?
|
| Wound Healing | 2 | 2018 | 344 | 0.240 |
Why?
|
| Case-Control Studies | 6 | 2020 | 1804 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 4 | 2019 | 746 | 0.230 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 178 | 0.230 |
Why?
|
| Janus Kinases | 1 | 2023 | 23 | 0.230 |
Why?
|
| Insurance Claim Review | 3 | 2015 | 41 | 0.230 |
Why?
|
| Anti-Ulcer Agents | 1 | 2003 | 22 | 0.230 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2016 | 76 | 0.230 |
Why?
|
| Ulcer | 2 | 2022 | 36 | 0.230 |
Why?
|
| Tertiary Care Centers | 3 | 2019 | 93 | 0.220 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2022 | 229 | 0.220 |
Why?
|
| Enteritis | 1 | 2002 | 21 | 0.220 |
Why?
|
| Enterocolitis | 1 | 2022 | 12 | 0.220 |
Why?
|
| Takayasu Arteritis | 1 | 2002 | 4 | 0.220 |
Why?
|
| Maintenance Chemotherapy | 2 | 2019 | 76 | 0.220 |
Why?
|
| Colonic Polyps | 2 | 2018 | 126 | 0.210 |
Why?
|
| Rectal Fistula | 1 | 2002 | 18 | 0.210 |
Why?
|
| Risk Assessment | 6 | 2020 | 2261 | 0.210 |
Why?
|
| Delayed-Action Preparations | 3 | 2017 | 116 | 0.210 |
Why?
|
| Administration, Rectal | 2 | 2015 | 12 | 0.210 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 147 | 0.210 |
Why?
|
| Budesonide | 2 | 2017 | 45 | 0.210 |
Why?
|
| Smoking | 3 | 2014 | 609 | 0.200 |
Why?
|
| Probiotics | 3 | 2008 | 81 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2022 | 144 | 0.200 |
Why?
|
| Anastomosis, Surgical | 4 | 2022 | 267 | 0.190 |
Why?
|
| Natalizumab | 3 | 2015 | 21 | 0.190 |
Why?
|
| Precancerous Conditions | 2 | 2016 | 196 | 0.190 |
Why?
|
| Chicago | 4 | 2018 | 1379 | 0.190 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 20 | 0.190 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 19 | 0.190 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.190 |
Why?
|
| Intestine, Small | 1 | 2002 | 303 | 0.180 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 37 | 0.180 |
Why?
|
| Digestive System Diseases | 1 | 2020 | 18 | 0.180 |
Why?
|
| Cohort Studies | 7 | 2022 | 2767 | 0.180 |
Why?
|
| Emergency Service, Hospital | 2 | 2015 | 484 | 0.180 |
Why?
|
| Metronidazole | 1 | 2019 | 26 | 0.180 |
Why?
|
| Surgical Wound Infection | 2 | 2022 | 184 | 0.180 |
Why?
|
| Acute Disease | 3 | 2019 | 826 | 0.180 |
Why?
|
| Aspirin | 1 | 2021 | 156 | 0.180 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 16 | 0.180 |
Why?
|
| Sickness Impact Profile | 1 | 1999 | 27 | 0.180 |
Why?
|
| Drug Substitution | 1 | 2019 | 25 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 153 | 0.170 |
Why?
|
| Ileal Diseases | 1 | 2019 | 25 | 0.170 |
Why?
|
| C-Reactive Protein | 4 | 2023 | 190 | 0.170 |
Why?
|
| Age Factors | 4 | 2016 | 1849 | 0.170 |
Why?
|
| Time Factors | 7 | 2019 | 5209 | 0.170 |
Why?
|
| Infection Control | 1 | 2020 | 115 | 0.170 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 71 | 0.170 |
Why?
|
| Integrins | 1 | 2019 | 76 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 589 | 0.170 |
Why?
|
| Guanine Nucleotides | 1 | 2018 | 14 | 0.170 |
Why?
|
| Costs and Cost Analysis | 3 | 2006 | 153 | 0.160 |
Why?
|
| Thionucleotides | 1 | 2018 | 56 | 0.160 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 999 | 0.160 |
Why?
|
| Vitamin D | 2 | 2021 | 261 | 0.160 |
Why?
|
| Pyrroles | 1 | 2019 | 184 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2018 | 118 | 0.150 |
Why?
|
| Comorbidity | 2 | 2015 | 943 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 159 | 0.150 |
Why?
|
| Carcinogenesis | 1 | 2019 | 195 | 0.150 |
Why?
|
| Pregnancy | 7 | 2020 | 2893 | 0.150 |
Why?
|
| Prednisone | 5 | 2012 | 258 | 0.150 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 67 | 0.150 |
Why?
|
| Vaccines | 1 | 2017 | 80 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2020 | 572 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2019 | 370 | 0.140 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2019 | 120 | 0.140 |
Why?
|
| Clostridium Infections | 1 | 2018 | 125 | 0.140 |
Why?
|
| JC Virus | 1 | 2015 | 5 | 0.130 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2015 | 13 | 0.130 |
Why?
|
| Disease Progression | 2 | 2019 | 1531 | 0.130 |
Why?
|
| Survival Rate | 4 | 2014 | 1860 | 0.130 |
Why?
|
| Sick Leave | 1 | 2015 | 13 | 0.130 |
Why?
|
| Infant, Newborn | 6 | 2020 | 2378 | 0.130 |
Why?
|
| Immunoglobulins | 1 | 2016 | 148 | 0.130 |
Why?
|
| Drug Costs | 2 | 2010 | 62 | 0.130 |
Why?
|
| Prescription Drugs | 1 | 2015 | 36 | 0.130 |
Why?
|
| Certolizumab Pegol | 1 | 2014 | 19 | 0.130 |
Why?
|
| Melanoma | 1 | 2019 | 454 | 0.120 |
Why?
|
| Men | 1 | 1994 | 10 | 0.120 |
Why?
|
| Injections, Intravenous | 3 | 2018 | 244 | 0.120 |
Why?
|
| Internal-External Control | 1 | 1994 | 44 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 295 | 0.120 |
Why?
|
| Women | 1 | 1994 | 25 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2017 | 329 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 293 | 0.120 |
Why?
|
| Mucous Membrane | 1 | 2013 | 83 | 0.120 |
Why?
|
| Neoplasms | 3 | 2020 | 2897 | 0.110 |
Why?
|
| Interferons | 2 | 2004 | 133 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 1994 | 204 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2000 | 754 | 0.110 |
Why?
|
| Biomarkers | 4 | 2021 | 1718 | 0.110 |
Why?
|
| Logistic Models | 5 | 2018 | 1185 | 0.110 |
Why?
|
| Health Status | 1 | 1994 | 360 | 0.100 |
Why?
|
| Odds Ratio | 5 | 2014 | 678 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 141 | 0.100 |
Why?
|
| Attitude | 1 | 2012 | 127 | 0.100 |
Why?
|
| Postoperative Period | 3 | 2021 | 303 | 0.100 |
Why?
|
| Nicotine | 2 | 2006 | 194 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 426 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2014 | 427 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 1990 | 0.090 |
Why?
|
| Child | 4 | 2022 | 6926 | 0.090 |
Why?
|
| Prevalence | 4 | 2008 | 1239 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2017 | 1823 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 1019 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 857 | 0.090 |
Why?
|
| Canada | 1 | 2010 | 204 | 0.090 |
Why?
|
| Smoking Cessation | 1 | 2012 | 230 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2705 | 0.090 |
Why?
|
| Europe | 1 | 2010 | 309 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2018 | 181 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2019 | 285 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 2436 | 0.080 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2008 | 24 | 0.080 |
Why?
|
| Retreatment | 2 | 2017 | 107 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2019 | 684 | 0.080 |
Why?
|
| Arthritis, Psoriatic | 1 | 2008 | 32 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 6501 | 0.080 |
Why?
|
| Inpatients | 2 | 2021 | 297 | 0.080 |
Why?
|
| Sex Factors | 3 | 2000 | 1054 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2012 | 2501 | 0.080 |
Why?
|
| Incidence | 5 | 2014 | 1576 | 0.080 |
Why?
|
| Medicare | 2 | 2021 | 406 | 0.080 |
Why?
|
| Propensity Score | 2 | 2018 | 136 | 0.080 |
Why?
|
| Drug Administration Routes | 1 | 2006 | 19 | 0.070 |
Why?
|
| Heart Diseases | 1 | 1989 | 290 | 0.070 |
Why?
|
| Reoperation | 2 | 2019 | 597 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2014 | 229 | 0.070 |
Why?
|
| Fatty Acids, Volatile | 1 | 2006 | 32 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 166 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2006 | 95 | 0.070 |
Why?
|
| Antibodies, Bacterial | 2 | 2017 | 95 | 0.070 |
Why?
|
| Triturus | 1 | 2005 | 1 | 0.070 |
Why?
|
| Multiple Sclerosis | 1 | 2008 | 262 | 0.070 |
Why?
|
| Heparin | 1 | 2006 | 175 | 0.070 |
Why?
|
| Anal Canal | 1 | 2006 | 89 | 0.070 |
Why?
|
| Sex Distribution | 3 | 2014 | 173 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2019 | 812 | 0.060 |
Why?
|
| Plasmapheresis | 1 | 2004 | 26 | 0.060 |
Why?
|
| Cause of Death | 1 | 2006 | 277 | 0.060 |
Why?
|
| Phenotype | 2 | 2022 | 2377 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2006 | 227 | 0.060 |
Why?
|
| Tablets | 1 | 2006 | 118 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 674 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2018 | 596 | 0.060 |
Why?
|
| Butyrates | 1 | 2004 | 42 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2005 | 164 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2004 | 119 | 0.060 |
Why?
|
| Antibodies | 1 | 2006 | 350 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2006 | 182 | 0.060 |
Why?
|
| Decision Trees | 1 | 2004 | 63 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1673 | 0.060 |
Why?
|
| Thiazoles | 1 | 2004 | 131 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 860 | 0.060 |
Why?
|
| Constriction, Pathologic | 2 | 2006 | 213 | 0.060 |
Why?
|
| Gastritis | 1 | 2004 | 32 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2006 | 597 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2004 | 156 | 0.060 |
Why?
|
| Phenylhydrazines | 1 | 2003 | 10 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 236 | 0.060 |
Why?
|
| Placebos | 1 | 2003 | 218 | 0.060 |
Why?
|
| Research Design | 1 | 2006 | 594 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2004 | 151 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 567 | 0.060 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 2002 | 8 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2004 | 267 | 0.050 |
Why?
|
| Collagen | 1 | 2004 | 269 | 0.050 |
Why?
|
| Parenteral Nutrition | 1 | 2002 | 60 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 76 | 0.050 |
Why?
|
| Radiology Department, Hospital | 1 | 2002 | 27 | 0.050 |
Why?
|
| Weight Loss | 1 | 2004 | 229 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2002 | 16 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2002 | 105 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 1565 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2002 | 29 | 0.050 |
Why?
|
| Illinois | 2 | 2017 | 462 | 0.050 |
Why?
|
| Cytokines | 1 | 2005 | 776 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2001 | 60 | 0.050 |
Why?
|
| Infant | 2 | 2018 | 3045 | 0.050 |
Why?
|
| Rectum | 1 | 2002 | 146 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 304 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2002 | 182 | 0.050 |
Why?
|
| Algorithms | 2 | 2006 | 1830 | 0.050 |
Why?
|
| Injections | 1 | 2001 | 109 | 0.050 |
Why?
|
| Ostomy | 1 | 2020 | 15 | 0.050 |
Why?
|
| Polyarteritis Nodosa | 1 | 1980 | 7 | 0.050 |
Why?
|
| Contract Services | 1 | 2000 | 5 | 0.050 |
Why?
|
| Fees, Medical | 1 | 2000 | 10 | 0.050 |
Why?
|
| Hospital Departments | 1 | 2000 | 12 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2004 | 710 | 0.050 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2000 | 41 | 0.050 |
Why?
|
| Hospital Charges | 1 | 2000 | 29 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 927 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2000 | 92 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 451 | 0.050 |
Why?
|
| France | 1 | 2019 | 47 | 0.040 |
Why?
|
| Thalidomide | 1 | 1999 | 54 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2000 | 59 | 0.040 |
Why?
|
| Biopsy | 2 | 2018 | 1161 | 0.040 |
Why?
|
| Surgery Department, Hospital | 1 | 2000 | 42 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 39 | 0.040 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2019 | 15 | 0.040 |
Why?
|
| Ileostomy | 1 | 2019 | 30 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 40 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2000 | 104 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 51 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 864 | 0.040 |
Why?
|
| Health Services Research | 1 | 1999 | 136 | 0.040 |
Why?
|
| Prednisolone | 1 | 2018 | 41 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 307 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 154 | 0.040 |
Why?
|
| Maternal Exposure | 1 | 2018 | 57 | 0.040 |
Why?
|
| Tetanus Toxin | 1 | 2017 | 2 | 0.040 |
Why?
|
| Haemophilus influenzae | 1 | 2017 | 13 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 526 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 72 | 0.040 |
Why?
|
| Data Collection | 1 | 1999 | 372 | 0.040 |
Why?
|
| Age Distribution | 2 | 2014 | 204 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 91 | 0.040 |
Why?
|
| Medical Records | 1 | 2017 | 119 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 381 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2018 | 373 | 0.040 |
Why?
|
| Length of Stay | 1 | 2000 | 700 | 0.040 |
Why?
|
| Hearing Loss | 1 | 1997 | 56 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 357 | 0.040 |
Why?
|
| Occludin | 1 | 2016 | 66 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2016 | 86 | 0.040 |
Why?
|
| Haemophilus Vaccines | 1 | 2016 | 5 | 0.040 |
Why?
|
| Tetanus Toxoid | 1 | 2016 | 10 | 0.040 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2016 | 70 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 199 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 327 | 0.030 |
Why?
|
| Mycophenolic Acid | 2 | 2006 | 87 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 970 | 0.030 |
Why?
|
| Animals | 2 | 2005 | 26581 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2017 | 298 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 712 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 1996 | 177 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 1999 | 454 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 151 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2015 | 55 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2016 | 129 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 685 | 0.030 |
Why?
|
| Kidney | 1 | 2001 | 1241 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 458 | 0.030 |
Why?
|
| Life Change Events | 1 | 1994 | 48 | 0.030 |
Why?
|
| Longevity | 1 | 1994 | 51 | 0.030 |
Why?
|
| Integrin alpha4 | 1 | 2013 | 11 | 0.030 |
Why?
|
| Contrast Media | 1 | 2019 | 1077 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2013 | 130 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 66 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2006 | 839 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1994 | 238 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 912 | 0.030 |
Why?
|
| Ploidies | 1 | 1991 | 40 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 2357 | 0.020 |
Why?
|
| Tobacco Use Disorder | 1 | 2012 | 108 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 3611 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1991 | 265 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1991 | 116 | 0.020 |
Why?
|
| Death Certificates | 1 | 1989 | 11 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 1989 | 59 | 0.020 |
Why?
|
| Milk, Human | 1 | 2009 | 43 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 287 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1991 | 579 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 1994 | 1621 | 0.020 |
Why?
|
| Health Surveys | 1 | 1989 | 239 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 376 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2009 | 233 | 0.020 |
Why?
|
| Mutation | 1 | 2019 | 3967 | 0.020 |
Why?
|
| Defecation | 1 | 2006 | 23 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2006 | 248 | 0.020 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2005 | 28 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 355 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2006 | 272 | 0.020 |
Why?
|
| Fetal Growth Retardation | 1 | 2005 | 66 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2004 | 63 | 0.020 |
Why?
|
| Gestational Age | 1 | 2005 | 311 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 2004 | 66 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1538 | 0.010 |
Why?
|
| Minnesota | 1 | 1980 | 46 | 0.010 |
Why?
|
| Electromyography | 1 | 1999 | 183 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1749 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1980 | 299 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1980 | 85 | 0.010 |
Why?
|
| Noise | 1 | 1997 | 27 | 0.010 |
Why?
|
| California | 1 | 1997 | 138 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 1997 | 80 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1991 | 66 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1991 | 364 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1991 | 1937 | 0.000 |
Why?
|